Assessment of SARS-CoV-2neutralizing antibodies inLuxembourg through novel highlysensitive NanoLuciferase-basedhigh throughput assays

Project Details

Description

In February 2020 the World Health Organization declared the outbreak of SARS-CoV-2, the new coronaviruscausing a severe acute respiratory syndrome (COVID-19) as a pandemic. Accurate monitoring of the population toidentify infected individuals and assess their degree of immune protection against the virus is therefore crucial. Ithas been previously shown that neutralising antibodies (NAbs) can confer protection against viral infections,including those caused by coronaviruses.Our consortium composed of the Luxembourg Institute of Health and Laboratoires Réunis Luxembourg intends tojoin their forces and competences to develop an ultrasensitive high-throughput platform for the detection,quantification and characterisation of NAbs against the new coronavirus in order to provide reliable information onthe prevalence and protection against SARS-CoV-2 in the Grand Duchy.
AcronymNanoLux SARS-CoV-2
StatusActive
Effective start/end date1/09/2014/07/23

Funding

  • FNR - Fonds National de la Recherche: €211,293.00
  • Laboratoires Réunis S.A.: €37,500.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.